Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arthritis Care Res (Hoboken) ; 72(9): 1266-1274, 2020 09.
Article in English | MEDLINE | ID: mdl-31199593

ABSTRACT

OBJECTIVE: To explore whether anxiety and depression are associated with clinical measures of disease for adolescent patients with juvenile idiopathic arthritis (JIA) and whether anxiety and depression are associated with increased peripheral proinflammatory cytokine levels in adolescent patients with JIA and in healthy adolescent controls. METHODS: A total of 136 patients with JIA and 88 healthy controls ages 13-18 years completed questionnaires on anxiety and depressive symptoms. For patients with JIA, pain, disability, physician global assessment (using a visual analog scale [VAS]), and number of joints with active inflammation (active joint count) were recorded. In a subsample, we assessed lipopolysaccharide-stimulated interleukin 6 (IL-6) production from peripheral blood mononuclear cells, serum IL-6, cortisol, and C-reactive protein levels. Data were analyzed by linear regression analysis. RESULTS: Levels of anxiety and depressive symptoms in patients with JIA were not significantly different than those in healthy controls. For patients with JIA, anxiety was significantly associated with disability (ß = 0.009, P = 0.002), pain (ß = 0.029, P = 0.011), and physician global assessment VAS (ß = 0.019, P = 0.012), but not with active joint count (ß = 0.014, P = 0.120). Anxiety was not associated with any laboratory measures of inflammation for JIA patients. These relationships were also true for depressive symptoms. For healthy controls, there was a trend toward an association of anxiety (but not depressive symptoms) with stimulated IL-6 (ß = 0.004, P = 0.052). CONCLUSION: Adolescent patients with JIA experience equivalent levels of anxiety and depressive symptoms as healthy adolescents. For adolescent patients with JIA, anxiety and depressive symptoms are associated with pain, disability, and physician global assessment VAS, but not with inflammation.


Subject(s)
Anxiety/complications , Arthritis, Juvenile/complications , Inflammation/complications , Pain/complications , Adolescent , Anxiety/psychology , Arthritis, Juvenile/blood , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/psychology , Case-Control Studies , Disability Evaluation , Female , Humans , Inflammation/blood , Inflammation/psychology , Interleukin-6/blood , Male , Pain/psychology , Pain Measurement , Severity of Illness Index
2.
Clin Exp Rheumatol ; 37 Suppl 121(6): 48-51, 2019.
Article in English | MEDLINE | ID: mdl-31172922

ABSTRACT

OBJECTIVES: Behçet's syndrome (BS) is a rare multi-system inflammatory disorder. Clinical phenotypic variance across geographical regions is recognised but UK BS patients' variance by age groups and gender has not been studied. This study compares the clinical features of adult and juvenile onset Behçet's Syndrome (JBS) in a UK population. METHODS: Two clinical databases of BS patients were compared. The JBS database was collected at the Great Ormond Street Hospital for Children, London (n=46). The adult database was collected at the Hammersmith Hospital, London (n=560). RESULTS: Oro-genital aphthosis had high prevalence in both the JBS and the adult cohort (oral: 97.8% vs. 96.6%, genital: 73.9% vs. 75.7%). The JBS cohort was more likely to have gastrointestinal involvement (21.7% vs. 4.5%, p<0.001) and arthritis (21.7% vs. 9.6%, p=0.021) compared to adults. The JBS cohort was less likely to have eye involvement (4.3% vs. 37%, p<0.001), skin (21.7% vs. 55.4%, p<0.001) and vascular involvement (6.5% vs. 17.5% p=0.063). JBS females had a higher rate of genital aphthosis than JBS males (87.5% vs. 59.1%, p=0.044). Adult females had higher rates of genital (85.2% vs. 64.5%, p<0.001) and oral (99.0% vs. 93.8%, p=0.001) aphthosis than adult males. Adult males were more likely to have ophthalmological (44.9% vs. 30.3%, p<0.001) and vascular (23.0% vs. 12.8%, p=0.002) manifestations than adult females. CONCLUSIONS: UK JBS patients displayed less ocular and skin manifestations compared to the adult BS patients. This information will aid clinicians in diagnosing BS in UK adult and paediatric populations.


Subject(s)
Behcet Syndrome , Adult , Age Factors , Age of Onset , Behcet Syndrome/pathology , Behcet Syndrome/physiopathology , Child , Cohort Studies , Female , Genital Diseases, Female/diagnosis , Genital Diseases, Female/etiology , Genital Diseases, Male/diagnosis , Genital Diseases, Male/etiology , Humans , Male , Retinal Vasculitis/diagnosis , Retinal Vasculitis/etiology , Sex Factors , Stomatitis, Aphthous/diagnosis , Stomatitis, Aphthous/etiology , Symptom Assessment , United Kingdom
3.
Rheumatology (Oxford) ; 57(8): 1381-1389, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29697850

ABSTRACT

Objectives: To determine if depressive symptoms assessed near diagnosis associate with future measures of pain, disability and disease for adolescent patients diagnosed with JIA. Methods: Data were analysed from JIA patients aged 11-16 years recruited to the Childhood Arthritis Prospective Study, a UK-based inception cohort of childhood-onset arthritis. Depressive symptoms (using the Mood and Feelings Questionnaire; MFQ), active and limited joint count, disability score (Childhood Health Assessment Questionnaire), pain visual analogue scale and patient's general evaluation visual analogue scale were collected. Associations between baseline measures (first visit to paediatric rheumatologist) were analysed using multiple linear regression. Linear mixed-effect models for change in the clinical measures of disease over 48 months were estimated including MFQ as an explanatory variable. Results: Data from 102 patients were analysed. At baseline, median (IQR) age was 13.2 years (11.9-14.2 years) and 14.7% scored over the MFQ cut-off for major depressive disorder. At baseline, depressive symptoms significantly associated with all clinical measures of disease (P ⩽ 0.01). High baseline depressive symptoms scores predicted worse pain (P ⩽ 0.005) and disability (P ⩽ 0.001) 12 months later but not active and limited joint counts. Conclusions: Adolescent patients with JIA and depressive symptoms had more active joints, pain and disability at the time of their first specialist appointment. The associations between baseline depression and both pain and disability continued for at least one year, however, this was not the case for active joint count.


Subject(s)
Arthritis, Juvenile/complications , Depression/diagnosis , Disability Evaluation , Disabled Persons/rehabilitation , Health Status , Quality of Life , Adolescent , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/rehabilitation , Child , Cross-Sectional Studies , Depression/etiology , Depression/rehabilitation , Female , Follow-Up Studies , Humans , Male , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires , Time Factors
4.
J Biol Chem ; 288(39): 28195-206, 2013 Sep 27.
Article in English | MEDLINE | ID: mdl-23935099

ABSTRACT

IL-2-inducible tyrosine kinase (Itk) plays a key role in antigen receptor signaling in T cells and is considered an important target for anti-inflammatory drug discovery. In order to generate inhibitors with the necessary potency and selectivity, a compound that targeted cysteine 442 in the ATP binding pocket and with an envisaged irreversible mode of action was designed. We incorporated a high degree of molecular recognition and specific design features making the compound suitable for inhaled delivery. This study confirms the irreversible covalent binding of the inhibitor to the kinase by x-ray crystallography and enzymology while demonstrating potency, selectivity, and prolonged duration of action in in vitro biological assays. The biosynthetic turnover of the kinase was also examined as a critical factor when designing irreversible inhibitors for extended duration of action. The exemplified Itk inhibitor demonstrated inhibition of both TH1 and TH2 cytokines, was additive with fluticasone propionate, and inhibited cytokine release from human lung fragments. Finally, we describe an in vivo pharmacodynamic assay that allows rapid preclinical development without animal efficacy models.


Subject(s)
Asthma/drug therapy , Cysteine/chemistry , Drug Design , Enzyme Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Adenosine Triphosphate/chemistry , Animals , Crystallography, X-Ray , Cytokines/metabolism , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemistry , Gene Expression Regulation, Enzymologic , Humans , Jurkat Cells , Leukocytes, Mononuclear/drug effects , Ligands , Male , Particle Size , Protein Binding , Protein-Tyrosine Kinases/chemistry , Rats , Rats, Wistar , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...